National study on pediatric acute encephalopathy in Japan (April 2020 to October 2023): Insights from the third study.

Publication date: Jun 25, 2025

Previous national studies of acute encephalopathy in Japan were conducted in 2007-2010 and 2014-2017. In this third study (April 1, 2020-October 31, 2023), spanning the coronavirus disease 2019 (COVID-19) outbreak, we compared results to assess trends in pediatric viral infections and therapeutic practices. Questionnaires were sent to 430 hospitals of the Japanese Pediatric Society, yielding 241 responses and 1197 cases. A secondary survey to 151 facilities received 110 responses (72. 8 %), identifying 622 eligible patients (604 for treatment, 544 for outcome analysis). Data on patient background, syndrome classification, causative virus, treatment, and prognosis were collected. Among 622 cases (54. 6 % boys), the highest incidence was in 1-year-olds, with case numbers peaking during COVID-19 and influenza outbreaks. The frequency of clinical syndromes was: acute encephalopathy with biphasic seizures and late reduced diffusion, 35. 1 %; clinically mild encephalitis/encephalopathy with a reversible splenial lesion, 17. 8 %; hemorrhagic shock and encephalopathy syndrome (HSES), 6. 9 %; acute encephalitis with refractory, repetitive partial seizures, 3. 7 %; acute fulminant cerebral edema (AFCE), 2. 2 %; acute necrotizing encephalopathy, 1. 6 %; and unclassifiable, 31. 4 %. Notably, the combined HSES/AFCE rate increased from 1. 9 % in the 2014-2017 survey to 9. 1 %, likely due to enhanced diagnosis and COVID-19 impact. Pathogens were exanthem subitum (16. 1 %), severe acute respiratory syndrome coronavirus 2 (15. 9 %), and influenza (7. 7 %). Treatments included steroid pulse therapy (68. 9 %), mitochondrial cocktails (42. 5 %), and targeted temperature management (31. 0 %). This study provides a comprehensive overview of pediatric acute encephalopathy during COVID-19 outbreaks, shows increases in the incidence of HSES/AFCE, and presents current treatment.

Concepts Keywords
Influenza Acute encephalopathy
Japanese Clinical syndromes
Therapy COVID-19
Pediatric neurology
SARS-CoV-2

Semantics

Type Source Name
disease MESH coronavirus disease 2019
disease MESH viral infections
disease MESH syndrome
disease MESH influenza
disease MESH seizures
disease MESH encephalitis
disease MESH encephalopathy
disease MESH hemorrhagic shock and encephalopathy syndrome
disease MESH cerebral edema
disease MESH Long Covid

Original Article

(Visited 16 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *